- Bristol Myers reaches a crossroads as a make-or-break year takes shapeBristol Myers Squibb is facing a bit of an identity crisis. CEO Chris Boerner is nearly two and a half years into his tenure, with most of his time defined byEndpoints · 2mo ago↗ source
- Pfizer earns positive Phase 3 in multiple myeloma; ICON overstated revenuePfizer’s positive Phase 3 data in multiple myeloma: The company’s Elrexfio produced a “statistically significant and clinically meaningful improvement” in progression-free survival in patients with…Endpoints · 2mo ago↗ source
- After Apellis deal, Biogen looks to fill early-stage pipelineBiogen is still looking at deals even after earmarking $5.6 billion to buy Apellis Pharmaceuticals earlier this month. “Most of what we're going to be focusing on is early-stage development and…